Molnupiravir still aids recovery from COVID-19: University of Oxford trial

Publication of the full results follows confusion over the use of the antiviral in Australia
Professor Michael Kidd
Professor Michael Kidd.

Molnupiravir speeds up recovery in high-risk patients with COVID-19 but has no effect on death or hospitalisations compared with usual care, confirm the long-awaited results from the PANORAMIC trial. 

The full findings from the UK-based randomised controlled study, which have now been peer reviewed and published in The Lancet, suggest the antiviral still has some advantage, including faster improvement of symptoms and reduction in viral load.